Want to see IN:EPIGRAL full AI Analyst Report?
EPIGRAL Stock Chart & Stats
₹1244.30
-₹4.30(-0.24%)
At close: 4:00 PM EST
₹1244.30
-₹4.30(-0.24%)
Day’s Range― - ―
52-Week Range₹806.20 - ₹2,114.30
Previous CloseN/A
Volume42.70K
Average Volume (3M)1.86K
Market Cap
₹50.24B
Enterprise Value₹40.59K
Total Cash (Recent Filing)₹54.60M
Total Debt (Recent Filing)₹5.72B
Price to Earnings (P/E)14.8
Beta1.49
Next Earnings
Jul 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)76.95
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.40
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.3
Revenue Forecast (FY)₹26.18B
Bulls Say, Bears Say
Bulls Say
Stronger Balance Sheet And Low LeverageLeverage reduced to ~0.26x and expanded equity materially improve financial flexibility and solvency. This durable balance-sheet repair lowers refinancing and distress risk, preserves room for capex or opportunistic M&A, and supports stability through chemical-cycle volatility over months.
Healthy Operating And Net MarginsSustained operating (~16%) and net (~13%) margins indicate structural pricing power and cost control relative to peers. These margin levels support durable cash earnings, fund reinvestment, and buffer against commodity swings, helping the business sustain returns across a 2–6 month horizon.
Attractive Return On Equity (~15%)ROE around 15% reflects continued efficient use of shareholder capital versus peers. Even with some downward trend, this level supports long-term shareholder value creation potential, enabling the firm to reinvest profitably and maintain competitive positioning over the coming months.
Bears Say
Weak Free Cash Flow And Cash ConversionNegative latest-year free cash flow and mixed cash conversion are structural concerns: they limit internal funding for capex, working-capital cushions, and dividends. Persistent FCF weakness signals earnings may not translate to liquidity, constraining strategy and increasing reliance on external financing.
Stagnant/soft Revenue GrowthFlat year-over-year revenue removes top-line momentum that underpins durable margin expansion and scale benefits. In a cyclical chemicals industry, lack of revenue growth forces reliance on margin recovery or balance-sheet maneuvers to sustain returns, raising medium-term execution risk.
Margin Compression And Earnings VolatilityMaterial compression of gross and operating margins increases earnings volatility and weakens profit resilience. For a capital-intensive chemicals firm, recurring margin swings complicate planning and may erode ROE and cash generation if not reversed, posing a sustained operational risk.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹806.20 and its highest was ₹2114.30 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹50.24B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is Jul 27, 2026 which is in 4 days.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on May 02, 2026. The company reported ₹18.764 earnings per share for the quarter, beating the consensus estimate of ₹14.3 by ₹4.464.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.44%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹18.764 in its last earnings report, beating expectations of ₹14.3. Following the earnings report the stock price went up 0.894%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash. Additionally, the company is involved in the trading of agrochemical products. Epigral caters to an extensive list of industries, including CPVC pipes and fittings, wind energy, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soaps and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. Incorporated in 2007 and based in Ahmedabad, India, the company was formerly known as Meghmani Finechem Limited until it adopted the name Epigral Limited in August 2023.
Technical Analysis
Deepak Nitrite Limited
―
Gujarat Alkalies & Chemicals Ltd.
―
Indo Amines Limited
―
Styrenix Performance Materials Ltd
―
Valiant Organics Limited
―